S&P Capital IQ Initiates Coverage on Medifocus, Inc. in Standard & Poor’s Factual Stock Reports
September 24 2012 - 9:37AM
Business Wire
S&P Capital IQ announced today that it has commenced
Standard & Poor’s Factual Stock Report coverage on Medifocus,
Inc.
Medifocus, Inc. (TSXV: MFS, OTC: MDFZF.PK) develops and
commercializes minimally invasive, focused-heat treatment devices
and systems. The Company has developed two advanced therapeutic
products: Prolieve, for the treatment of BPH (Benign Prostatic
Hyperplasia), acquired from Boston Scientific in July 2012, and the
APA-1000, microwave technology, for treatment of Breast Cancer.
Prolieve is a FDA approved commercial product and is generating
revenue. The APA-1000 is in advanced stage of clinical development
and has received approval to enter the final pivotal phase-III
clinical trial, the final step before commercial approval.
Medifocus has a device treatment pipeline of additional therapies
based on its existing comprehensive portfolio of patented
technologies.
The Prolieve System is a medical device that both heats the
prostate and dilates the prostatic urethra. The Prolieve System is
the only minimally invasive treatment option for the symptoms of
enlarged prostate (BPH) in men indicated by the FDA as an in office
treatment alternative to drug therapy. Medifocus is well positioned
to address the $8 billion market for BHP treatments thru
traditional sales channels and its unique mobile treatment service.
The acquisition of Prolieve transforms Medifocus from a development
stage medical device company to a mature medical treatment and
device company with a revenue-generating commercial product.
Medifocus' APA 1000 breast cancer treatment system is a
focused-heat treatment that can improve the efficacy of
neo-adjuvant chemotherapy in shrinking large breast cancer tumors,
improving the chance of breast conservation, and decreasing the
need for radical breast surgery. Focused microwaves can be used to
shrink breast tumors up to eight cm in diameter improving the
chance of breast conservation for these patients. The first
indication for treatment of medium sized breast tumors has a total
addressable marketplace of $4 billion.
The company's goal is to improve outcomes and standards of care
by deploying minimally invasive treatments and devices. Using the
Prolieve technology platform and the APA focused-heat platform, the
Company is well positioned to develop a rich pipeline of minimally
invasive and side effect-free focused-heat treatment systems and
devices for cancer and other diseases.
Standard & Poor’s Factual Stock Report coverage on Medifocus
Inc will also be accessible on an ongoing basis to the investment
community by scores of buy-side institutions and sell-side firms
that utilize S&P Capital IQ research and information platforms
daily. Millions of self-directed investors also have access to the
report via their e-brokerage accounts. Please visit
www.medifocusinc.com for additional information.
About Standard & Poor's Factual Stock Reports
Currently profiling approximately 500 issuers, Standard &
Poor’s Factual Stock Reports, produced by S&P Capital IQ,
increase market awareness of issuers in the investment community
with insightful commentary and key statistics and information.
Standard & Poor’s Factual Stock Reports provide factual
research coverage about company fundamentals and business
prospects, thereby enabling information about covered companies to
reach a wide investor audience of Buy and Sell-side investors.
Updated weekly with the latest pricing, trading volume, and other
data, the reports include recent developments, a financial review,
key operating information, industry and peer comparisons,
institutional holdings analysis, Street Consensus and opinions,
performance charts, business summary, fundamental data, and news.
Because coverage of these reports is underwritten by the issuer,
S&P Capital IQ does not offer investment opinions concerning
the advisability of investing in these stocks.
Standard & Poor’s Factual Stock Reports are produced
separately from any other analytic activity of S&P Capital IQ
or related organizations. S&P Capital IQ does not trade on its
own account.
About S&P Capital IQ
S&P Capital IQ, a business line of The McGraw-Hill Companies
(NYSE:MHP), is a leading provider of multi-asset class and real
time data, research and analytics to institutional investors,
investment and commercial banks, investment advisors and wealth
managers, corporations and universities around the world. We
provide a broad suite of capabilities designed to help track
performance, generate alpha, and identify new trading and
investment ideas, and perform risk analysis and mitigation
strategies. Through leading desktop solutions such as the S&P
Capital IQ, Global Credit Portal and MarketScope Advisor desktops;
enterprise solutions such as S&P Capital IQ Valuations, and
Compustat; and research offerings, including Leveraged Commentary
& Data, Global Markets Intelligence, and company and funds
research, S&P Capital IQ sharpens financial intelligence into
the wisdom today’s investors need. For more information visit
www.spcapitaliq.com.
Photos/Multimedia Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50418142&lang=en
Medifocus (CE) (USOTC:MDFZF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Medifocus (CE) (USOTC:MDFZF)
Historical Stock Chart
From Aug 2023 to Aug 2024